VivoSeq
Hematology

Myelofibrosis，mf

2

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Myelofibrosis，MF is an early-stage landscape with 2 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical1

Roginolisib

iOnctura

Phase 1
No programs
Phase 21

Pacritinib

OrsoBio, Inc

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)
Recruiting·IiOnctura·Preclinical·NCT06887803·26 enrolled
Pacritinib For The Reduction Of Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia; A Multicenter, Open-Label, Single Arm, Phase II Exploratory Study
Recruiting·GGrupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas·Phase 2·NCT07394153·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)